Loading patent…
AssigneesInternational Institute of Cancer Immunology, Inc., Sumitomo Dainippon Pharma Co., Ltd.
InventorHaruo SUGIYAMA
Estimating the term…
The present disclosure provides a composition for preventing or treating a benign tumor. Provided is a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a specific embodiment, the present disclosure provides a composition for preventing or treating a benign tumor that comprises a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof. In a preferred embodiment, the composition for preventing or treating a benign tumor (e.g. familial adenomatous polyposis) according to the present disclosure comprises a killer type WT1 peptide and/or a helper type WT1 peptide. In a further preferred embodiment, the WT1 peptide is WT1126 killer peptide and/or WT135 helper peptide. In another aspect, provided are a method of inducing WT1 peptide-specific CTLs, a method of inducing WT1-specific helper T cells, and a method of inducing dendritic cells presenting a WT1 peptide.
A composition for preventing or treating a benign tumor, comprising a WT1 peptide or an analog thereof.
A composition for preventing or treating a benign tumor, comprising a nucleic acid molecule encoding a WT1 peptide or an analog thereof.
A composition for inducing WT1-specific CTLs and/or WT1-specific helper T cells, comprising a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof, wherein the composition is for use in preventing or treating a benign tumor.
A composition for inducing WT1-presenting dendritic cells, comprising a WT1 peptide or an analog thereof, or a nucleic acid molecule encoding a WT1 peptide or an analog thereof, wherein the composition is for use in preventing or treating a benign tumor.
A composition for preventing or treating a benign tumor, comprising WT1-specific CTLs and/or WT1-specific helper T cells.
A composition for preventing or treating a benign tumor, comprising WT1-presenting dendritic cells.
A method of preventing or treating a benign tumor in a subject, comprising administering to the subject an effective amount of a WT1 peptide or an analog thereof.
A WT1 peptide or an analog thereof for preventing or treating a benign tumor.
Use of a WT1 peptide or an analog thereof in the manufacture of a composition for preventing or treating a benign tumor.
Dependencies are inferred from the claim text.